- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04478734
Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington's Disease (HUNTIAM)
Multicentric Trial on the Use of Combined Therapy of Thiamine and Biotine in Patients With Huntington´s Disease
Evaluate the safety and tolerability of combined oral thiamine with biotin therapy in patients with Huntington´s disease in mild to moderate stages and it is intended to evaluate the biological effect of the treatment in the central nervous system of these patients using as the main biomarker the increase in the level of thiamine monophosphate (TMP) in cerebrospinal fluid (CSF) of these patients with Huntington Disease (HD) during a follow-up period of one year.
Our main hypothesis is that combined thiamine-biotin oral therapy is a secure and well-tolerated treatment, potentially capable of modifying the disease course or avoiding the progression of symptoms in early-stages HD patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The assessment of the safety and tolerability of the combined oral thiamine and biotin therapy in patients with HD will be performed by:
- Periodic clinical examination and anamnesis directed by a neurologist during face-to-face and non-contact visits.
- The collection of adverse effects during interviews of face-to-face visits to assess tolerability.
- Analytical monitoring with hematological and biochemical control (hepatic and renal function) during the dose escalation period, subsequently being this periodic control every 3 months, from signature of informed consent until the end the follow up.
The evaluation of the biological efficacy of treatment with combined oral thiamine and biotin therapy in increasing thiamine monophosphate (TMP) levels in cerebrospinal fluid (CSF) of patients with HD is to be performed by:
- The determination of thiamine levels: free thiamine, TMP, and thiamine pyrophosphate (TTP) in CSF and blood of patients at the beginning and after the end of the study.
- Comparison of thiamine levels (free, TMP and TTP) between the start and the end of the study in CSF and serum of patients with HD.
The evaluation of the biological efficacy of the treatment with combined oral thiamine and oral biotin therapy in neurodegeneration produced in HD will be performed by:
- Measurement of neurofilament light chain protein (NfL) levels in CSF at the baseline visit and after the end of the treatment.
- The obtained score in the motor and Total Functional Capacity (TFC) section of the Unified Huntington's Disease Rating Scale (UHDRS).
- Measurement of bradykinesia through quantitative motion measurement techniques (Quantitative motor assessment, Q-motor). Q-motor assessment relies on three-dimensional position sensors and pre-calibrated force translators, for standardized movement recording. This measurement will be made to patients in the pre-selection visit, randomization, and quarterly face-to-face visits.
- Score on the quality of life scale (SF-36).
- Variation in the overall clinical impression scale of the patient and the examiner.
- Measurement of the change in the volume of the caudate nucleus, white matter, and cortical thickness, as well as in the change of the Combined cerebral atrophy score. Measurements of cerebral structures will be acquired on magnetic resonance imaging scans (3T) at the baseline visit and after the end of the treatment.
To determine the sample size required to examine secondary and exploratory objectives, we based our estimations on the published thiamine-biotin treatment effects in preclinical HD models, and on the reported differences in CSF thiamine levels between HD patients and healthy subjects (Pico S, et al. 2021). According to the previous results, it is expected that a medium-to-high effect size (0.6 ≤ Cohen's d ≥ 0.8) would be necessary to restore TPP, TMP and Free-thiamine levels in CSF after treatment. Based on the parameter choices, for a desired power of 0.80 and a Type I error rate of 0.05, we estimate that we would need 24 HD patients to detect a standardized mean difference of 0.6. Sample size analysis was conducted using GPower 3.1.9.7 software.
The demographic data collection as well as the information related to all the variables analyzed during the study will be done through an electronic data collection notebook. The notification of adverse effects, severity, and relationship with study medication will be done through an electronic data collection notebook.
All statistical analyses will be conducted using SPSS v.26.0. IBM software and R studio software package. Linear regression will be used when the variables are quantitative (eg, scale measurements, CSF thiamine or NfL levels, among others) controlling for age, sex, CAG repetitions and motor symptom severity (UHDRS and UHDRS-Total Functional Capacity) at baseline as potential confounding variables. Logistic or multinomial regression when the variables are groups (binary or multinomial).
We will examine the association between the severity of disease and CSF thiamine among HD patients by fitting a linear mixed model for each clinical measurement, with age, sex, CAG repetitions and disease severity (UHDRS-TFC) as the covariates.
Magnetic resonance imaging performed during the study will be processed with specific neuroimaging programs for volumetry, diffusion and cortical thickness.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Pablo Mir Rivera, MD/PhD
- Phone Number: +34 955923039
- Email: pmir@us.es
Study Contact Backup
- Name: Clara M. Rosso Fernández, MD/PhD
- Phone Number: +34 955012144
- Email: claram.rosso.sspa@juntadeandalucia.es
Study Locations
-
-
-
Sevilla, Spain, 41013
- Recruiting
- Hospital Virgen Del Rocio
-
Contact:
- Pablo Mir Rivera, MD
-
-
Seville
-
Sevilla, Seville, Spain, 41013
- Not yet recruiting
- Virgen del Rocio Hospital
-
Contact:
- Clara M Rosso Fernández, MD/PhD
- Phone Number: +34 955012144
- Email: claram.rosso.sspa@juntadeandalucia.es
-
Contact:
- Pablo Mir Rivera, MD/PhD
- Phone Number: +34955923039
- Email: pmir@us.es
-
Principal Investigator:
- Pablo Mir Rivera, MD/PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients of legal age with manifest Huntington's disease with motor symptoms (chorea, dystonia or bradykinesia) and/or neuropsychiatric; and genetic confirmation of a number of repetitions of the cytosine-adenine-guanine trinucleotide (CAG triplet) in the HTT gene (coding for HTT) greater than or equal to 39
- Patients should be capable of giving informed consent and attending the planned visit of the study.
- Women of childbearing age should obtain a negative result in the serum or urine pregnancy test at the screening visit. They must also accept the use of appropriate contraceptive methods during the course of the clinical trial and men who have a partner of childbearing age, accept the use of contraceptive methods
Exclusion Criteria:
- Medical comorbidities considered clinically significant by the clinical judgment of the investigators.
- Pregnancy or lactation
- Patients with HD dependents on the basic routine daily life activities (UHDRS TFC < 7) or a severe cognitive decline.
- Active psychosis at the moment of the screening evaluation.
- Severe renal failure.
- Patients previously treated with thiamine and/or biotin or enrolled in other HD clinical trial with oligonucleotide antisense (IONIS-HTTRX (RG6042).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Moderate doses
moderate doses of combination therapy applying the minimum average dosage of thiamine and biotin used in patients with BTBGD
|
Thiamine 600 mg every day + Biotin 150mg every day
Other Names:
|
Experimental: High doses
high doses of the combination therapy applying the average standard dosage of thiamine and biotin used in patients with BTBGD.
|
Thiamine 1200 mg every day + Biotin 300mg every day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events as assessed by clinical examination anamnesis and Analytical monitoring with hematological and biochemical control (hepatic and renal function)
Time Frame: From signature of informed consent form, at all scheduled visits, to end of follow up week 52
|
Patient´s condition and emergence of comorbidity by clinical examination and anamnesis directed by a neurologist, by measuring of vital signs (blood pressure, heart rate,breath rate weight and height)
|
From signature of informed consent form, at all scheduled visits, to end of follow up week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The evaluation of the efficacy of treatment with combined oral thiamine and biotin therapy in increasing thiamine monophosphate (TMP) levels in CSF of patients with HD
Time Frame: At baseline (week 0) and visit 8 (week 48)
|
Determination and comparison of thiamine levels (free, TMP and TTP) in CSF and blood at the beginning and the end of the treatment.
|
At baseline (week 0) and visit 8 (week 48)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the biological effect of the combined thiamine-biotin oral therapy in the neurodegeration of HD patients
Time Frame: At baseline (week 0) and visit 8 (week 48)
|
Measurement of the change in CSF NfL levels of patients with HD treated with the combined thiamine-biotin therapy
|
At baseline (week 0) and visit 8 (week 48)
|
Evaluate the biological effect of the combined thiamine-biotin oral therapy in the neuroimaging progression markers in patients with HD
Time Frame: At baseline (week 0) and visit 8 (week 48)
|
Measurement of the change in the volume of the caudate nucleus, white matter and cortical thickness, as well as in the combined cerebral atrophy score; comparing these values with those described in prospective registries of patients with HD.
|
At baseline (week 0) and visit 8 (week 48)
|
Evaluate the effect of the combined thiamine-biotin oral therapy in the quality of life of patients with HD
Time Frame: At baseline (week 0), week 24 and week 48
|
Changes in the 36-Item Short Form Health Survey (SF-36) score of the quality of life.
Short Form 36 Health Survey (SF-36 ) consists of 35 punctually items, divided into 8 dimensions: Physical Function, Physical Role, Emotional Role, Social Function, Mental Health, General Health, Body Pain and Vitality.
It also contains an additional item that is not part of any dimension and that measures the change in health over time.
The scores of the 8 dimensions of SF-36 are arranged in such a way that the higher the value recorded, the better the corresponding health status.
scale (SF-36).
|
At baseline (week 0), week 24 and week 48
|
Evaluate the clinical effect of the combined thiamine-biotin oral therapy in the severity of motor symptoms of patients with HD
Time Frame: At baseline (week 0), week 24 and week 48
|
Evaluate changes in the score of the UHDRS motor scale and UHDRS- Total functional capacity.
|
At baseline (week 0), week 24 and week 48
|
Evaluate the clinical effect of the combined thiamine-biotin oral therapy in the severity of bradykinesia of patients with HD.
Time Frame: At baseline (week 0), week 12, week 24, week 36 and week 48
|
Evaluate changes in the score of Quantitative-motor assessments (Q-motor).
Measurement of bradykinesia will be done through quantitative movement measurement techniques.
|
At baseline (week 0), week 12, week 24, week 36 and week 48
|
Evaluate the effect of the combined thiamine-biotin oral therapy in the global severity of disease of patients with HD
Time Frame: At baseline (week 0), week 24 and week 48
|
Changes in the score of The Clinical Global Impressions - Severity scale-S (CGI-C). The CGI provides a brief of the patient's global functioning prior to and after initiating a study medication. Comprises two measures evaluating the following: (a) severity of psychopathology from 1 to 7 and (b) change from the initiation of treatment on a similar seven-point scale. CGI-C scores range from 1 (very much improved) through to 7 (very much worse). |
At baseline (week 0), week 24 and week 48
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Pablo Mir Rivera, MD/PhD, Institute of Biomedicine of Seville (IBiS)
- Principal Investigator: Clara M. Rosso Fernández, Virgen del Rocío University Hospital Research and Clinical Trials Unit
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Genetic Diseases, Inborn
- Basal Ganglia Diseases
- Movement Disorders
- Neurodegenerative Diseases
- Dyskinesias
- Heredodegenerative Disorders, Nervous System
- Dementia
- Cognition Disorders
- Chorea
- Huntington Disease
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Vitamin B Complex
- Biotin
- Thiamine
Other Study ID Numbers
- HUNTIAM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Huntington Disease
-
University of IowaThe University of Texas Health Science Center, Houston; Children's Hospital... and other collaboratorsRecruitingJuvenile Huntington Disease | Juvenile-Onset Huntington DiseaseUnited States
-
Sanguine BiosciencesHoffmann-La RocheRecruitingHuntington Disease | Huntington's Dementia | Huntington Disease, Late Onset | Huntington; Dementia (Etiology)United States
-
PrileniaCompletedHealth Volunteers, Huntington DiseaseGermany
-
Assistance Publique - Hôpitaux de ParisCEACompletedBrain Neuroimaging Biomarkers in Huntington DiseaseFrance
-
European Huntington's Disease NetworkCompletedHuntington Disease, JuvenileGermany, United Kingdom
-
Novartis PharmaceuticalsCompletedEarly Manifest Huntington DiseaseCanada, Germany, France, Spain, Hungary
-
University Hospital, AngersCompletedPresymptomatic Huntington DiseaseFrance
-
SOM Innovation Biotech SAActive, not recruitingHuntington ChoreaSpain, Germany, Italy, United Kingdom, France, Poland, Switzerland
-
Neurocrine BiosciencesEnrolling by invitation
-
Neurocrine BiosciencesHuntington Study GroupActive, not recruitingChorea, HuntingtonUnited States, Canada
Clinical Trials on Moderate doses of Thiamine y Biotin
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedDiffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma | CD20-Positive Neoplastic Cells Present | Refractory Mature B-Cell Non-Hodgkin LymphomaUnited States
-
University of JenaCompletedAbortion, HabitualGermany, Austria